Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections among undocumented migrants and uninsured legal residents in the Netherlands: A cross-sectional study, 2018-2019.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
25
05
2021
accepted:
10
10
2021
entrez:
29
10
2021
pubmed:
30
10
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Migrants are not routinely screened for hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) in the Netherlands. We estimated the prevalence and determined factors associated with HBV, HCV and/or HIV infections among undocumented migrants and uninsured legal residents. In this cross-sectional study, undocumented migrants and uninsured legal residents were recruited at a non governmental organization (NGO), healthcare facility in the Netherlands and were invited to be tested for hepatitis B surface antigen (HBsAg), anti-hepatitis B core antibodies (anti-HBcAb), HCV-RNA, and anti-HIV antibodies or HIV antigen at a local laboratory. Of the 1376 patients invited, 784 (57%) participated. Participants originated from Africa (35%), Asia (30%) and North/South America (30%). 451/784 (58%) participants went to the laboratory for testing. Of participants 30% were HBV exposed (anti-HBcAb-positive), with 27% (n = 119/438, 95% CI 23.1% to 31.6%) having resolved HBV infection (HBsAg-negative) and 2.5% (n = 11/438, 95%CI 1.3% to 4.5%, 64% new infection) having chronic HBV infection (HBsAg-positive). Compared to HBV non-exposed, HBV exposed individuals were older (p = 0.034) and more often originated from Africa (p<0.001). Prevalence of chronic HCV infection (HCV-RNA-positive) was 0.7% (n = 3/435, 95%CI 0.1% to 2.0%, all new infections) and HIV infection 1.1% (n = 5/439, 95%CI 0.04% to 2.6%, 40% new infection). Prevalence of chronic HBV, chronic HCV and HIV infections in our study population is higher compared to the Dutch population, thus emphasizing the importance of case finding for these infections through primary care and public health in this specific group of migrants. Screening uptake could be improved by on-site testing.
Sections du résumé
BACKGROUND
Migrants are not routinely screened for hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) in the Netherlands. We estimated the prevalence and determined factors associated with HBV, HCV and/or HIV infections among undocumented migrants and uninsured legal residents.
METHODS
In this cross-sectional study, undocumented migrants and uninsured legal residents were recruited at a non governmental organization (NGO), healthcare facility in the Netherlands and were invited to be tested for hepatitis B surface antigen (HBsAg), anti-hepatitis B core antibodies (anti-HBcAb), HCV-RNA, and anti-HIV antibodies or HIV antigen at a local laboratory.
RESULTS
Of the 1376 patients invited, 784 (57%) participated. Participants originated from Africa (35%), Asia (30%) and North/South America (30%). 451/784 (58%) participants went to the laboratory for testing. Of participants 30% were HBV exposed (anti-HBcAb-positive), with 27% (n = 119/438, 95% CI 23.1% to 31.6%) having resolved HBV infection (HBsAg-negative) and 2.5% (n = 11/438, 95%CI 1.3% to 4.5%, 64% new infection) having chronic HBV infection (HBsAg-positive). Compared to HBV non-exposed, HBV exposed individuals were older (p = 0.034) and more often originated from Africa (p<0.001). Prevalence of chronic HCV infection (HCV-RNA-positive) was 0.7% (n = 3/435, 95%CI 0.1% to 2.0%, all new infections) and HIV infection 1.1% (n = 5/439, 95%CI 0.04% to 2.6%, 40% new infection).
CONCLUSION
Prevalence of chronic HBV, chronic HCV and HIV infections in our study population is higher compared to the Dutch population, thus emphasizing the importance of case finding for these infections through primary care and public health in this specific group of migrants. Screening uptake could be improved by on-site testing.
Identifiants
pubmed: 34714867
doi: 10.1371/journal.pone.0258932
pii: PONE-D-21-16533
pmc: PMC8555813
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0258932Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Epidemiol Infect. 2014 Oct;142(10):2140-6
pubmed: 24398373
Sex Transm Infect. 2015 Nov;91(7):467-72
pubmed: 26126531
Euro Surveill. 2015;20(35):30009
pubmed: 26530499
Euro Surveill. 2018 Mar;23(11):
pubmed: 29560855
BMC Public Health. 2014 Jan 22;14:66
pubmed: 24450797
J Hepatol. 2020 Nov;73(5):1170-1218
pubmed: 32956768
J Travel Med. 2015 Mar-Apr;22(2):78-86
pubmed: 25424439
J Hepatol. 2017 Jan;66(1):48-54
pubmed: 27592304
Open Forum Infect Dis. 2015 Oct 26;2(4):ofv162
pubmed: 26668814
Epidemiol Infect. 2019 Jan;147:e147
pubmed: 30869044
Infect Dis Poverty. 2017 Feb 9;6(1):33
pubmed: 28179020
BMC Infect Dis. 2011 Jun 30;11:185
pubmed: 21718466
Lancet. 2015 Oct 17;386(10003):1546-55
pubmed: 26231459
Sex Transm Infect. 2009 Aug;85(4):249-55
pubmed: 19103642
J Viral Hepat. 2017 Jul;24(7):526-540
pubmed: 28092419
BMC Public Health. 2016 May 23;16:426
pubmed: 27216405
Health Promot Int. 2014 Dec;29(4):692-704
pubmed: 23574695
J Big Data. 2018;5(1):43
pubmed: 30931238
Eur J Public Health. 2011 Jun;21(3):333-7
pubmed: 20813894
Infect Dis Poverty. 2019 Mar 15;8(1):17
pubmed: 30871599
World J Gastroenterol. 2017 Oct 14;23(38):7037-7046
pubmed: 29097876
J Hepatol. 2012 Dec;57(6):1171-6
pubmed: 22885717
Clin Infect Dis. 2012 Oct;55(8):1047-55
pubmed: 22875876
Int J Public Health. 2010 Oct;55(5):421-8
pubmed: 20502936
Curr Opin Infect Dis. 2018 Feb;31(1):25-32
pubmed: 29095720
PLoS One. 2018 Nov 8;13(11):e0207037
pubmed: 30408079
AIDS. 2017 Sep 10;31(14):1979-1988
pubmed: 28857779
Epidemiol Infect. 2012 Apr;140(4):724-30
pubmed: 21740610
JHEP Rep. 2019 May 31;1(2):71-80
pubmed: 32039354
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
Womens Health Issues. 2009 Jan-Feb;19(1):61-9
pubmed: 18951815
BMC Health Serv Res. 2018 Jan 18;18(1):30
pubmed: 29347933